Group 1 - Indivior PLC will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, with CEO Joe Ciaffoni and CFO Ryan Preblick hosting meetings and a fireside discussion [1] - The fireside discussion will be publicly available via a live webcast [1] - Indivior focuses on developing medicines for opioid use disorder (OUD) and aims to transform OUD into a recognized chronic disease [1] Group 2 - Indivior presented new real-world evidence at the AMCP Nexus 2025 conference, highlighting the clinical and economic benefits of adherence to monthly injectable buprenorphine [2] - The company reported its third-quarter financial results for 2025 and raised its full-year financial guidance [3]

Company Participation in Investor Events - Indivior PLC will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8th, where CEO Joe Ciaffoni and CFO Ryan Preblick will host meetings and a fireside discussion [1] - The company will also attend the H.C. Wainwright 27th Annual Global Investment Conference on September 9th, with similar meeting arrangements [2] Company Overview - Indivior is a global pharmaceutical company focused on developing medicines for opioid use disorder (OUD), aiming to transform OUD into a recognized chronic disease [3] - The company is headquartered in Richmond, VA, employs over 1,000 individuals globally, and its products are available in over 30 countries [3]